Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen
| Image |  |
|---|---|
| Description | scientific article published on 25 October 2020 |
| Author/s |
author: Anne-Geneviève Marcelin |
| Publication date | October 25, 2020 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |